Dr. Scott Rocklage Is Working For Cures Through Investing

Expansion Therapeutics is a company working to find a cure for Myotonic dystrophy type 1 also called DM 1. To aid in their search for a cure, Expansion Therapeutics is working to obtain financing. 5AM Ventures, which is headed by Scott Rocklage, is one of the major venture capital firms contributing to Expansion Therapeutics’ efforts. 5AM Ventures, working alongside several other groups, has helped raise over $55 million to help Expansion Therapeutics with its DM 1 research.

 

DM 1 occurs when RNA molecules are converted into proteins. The RNA levels in some people can reach a state where the muscles and the internal organs are seriously affected. DM 1 is a congenital condition, and it has been known to affect many members of the same family line.

 

Scott Rocklage has helped to bring a research team on board to aid Expansion Therapeutics in its quest to cure DM 1. Leading the research team will be Dr. Matthew D. Disney. He has been working on a cure for DM 1 for over the past 12 years.

 

Through his investment firm 5AM Ventures, Scott Rocklage is able to provide investment capital and management assistance to those working in various areas of medical research. Dr. Rocklage has provided the leadership needed to bring three drugs from the testing phase through FDA approval.

 

In addition to his work at 5AM Ventures, Dr. Rocklage has served as both chairman and CEO of Cubist Pharmaceuticals. He was also executive chairman of Semprus and Miikana. Scott Rocklage holds 30 patents for products for which he either invented or helped to invent.

 

Connect with Dr. Scott Rocklage on LinkedIn.

Jeremy Goldstein: Choosing Knockout Stock Options

It’s important that every corporation goes over their compensation method with their accountant on a regular basis. Things change quickly in the corporate world, and using an outdated or too risky method can leave the company and its employees in a world of hurt.

Employee benefits are something most new enterprises don’t think about until employees start asking for more than just a basic paycheck. Unfortunately, that puts a lot of these newer companies in a position to make a bad decision and leaves them or their employees vulnerable. Luckily, there are experts like Jeremy Goldstein to help them out.

Jeremy Goldstein has worked as a business lawyer for the last 15 years. He’s New York’s go-to guy when it comes to choosing the right compensation method, employee benefits, and sensitive situations. His law firm, Jeremy L. Goldstein and Associates, works mostly on an advisory level.

Executive compensation and corporate governance are two things Jeremy Goldstein knows better than anyone else. He’s a leading lawyer of business and has been recognized by several legal publications, including The Legal 500 and Chamber USA Guide to America’s Leader Lawyers for Business, for his expertise on both of these matters.

Currently, he’s trying to get more corporations to reintroduce stock options as employee benefits. In recent years, many top-name corporations stopped providing stock options in favor of less complicated compensation methods. Basically, everyone’s tired of the ups and downs and risks vs. rewards that come with stock options.

Employees prefer to have benefits that are more stable and reliable than stock options. Lately, more corporations have started proving higher salaries and wages, equities, or more specific insurance coverage. These compensation methods make employees happy immediately, whereas stock options may take years to make people feel valuable.

All of that aside, Jeremy Goldstein believes companies are missing out by eliminating stock options. Stock options are risky, but they have more advantages than disadvantages. For a start, they make employees directly responsible for the company’s stock value. When the company performs well, the stock value is higher, meaning workers are more likely to care about their work.

It’s just as important that corporations choose the right type of stock option; there’s more than one. Goldstein recommends that they take a look at “knockout” stock options. Knockout options come with all the rewards of their counterparts with much less risk. Learn more: https://www.crunchbase.com/person/jeremy-goldstein#/entity